NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bausch And Lomb	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	gramicidin; neomycin sulfate; polymyxin b sulfate	SOLUTION/DROPS;OPHTHALMIC	064047	ANDA	Bausch & Lomb Incorporated	24208-790-62	1 BOTTLE, DROPPER in 1 CARTON (24208-790-62) / 10 mL in 1 BOTTLE, DROPPER	1996-01-31
Bausch And Lomb	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	gramicidin; neomycin sulfate; polymyxin b sulfate	SOLUTION/DROPS;OPHTHALMIC	064047	ANDA	A-S Medication Solutions	50090-0247-0	1 BOTTLE, DROPPER in 1 CARTON (50090-0247-0) / 10 mL in 1 BOTTLE, DROPPER	1996-01-31
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

The integration of aminoglycosides and polypeptide antibiotics, such as Neomycin, Polymyxin B Sulfates, and Gramicidin, is critical within the antimicrobial pharmaceutical landscape. These agents serve pivotal roles in managing bacterial infections, particularly in topical and injectable formulations. Understanding the supply chain, key manufacturers, and market dynamics governing these compounds is essential for pharmaceutical companies, healthcare providers, and policymakers aiming to ensure dependable access and compliance with regulatory standards.

Overview of the Drugs

Neomycin

Neomycin is an aminoglycoside antibiotic primarily used topically for skin, eye, and ear infections, with occasional systemic applications. Its mechanism involves inhibiting bacterial protein synthesis, leading to bactericidal effects. The production spans chemical synthesis and microbial fermentation, predominantly from Streptomyces fradiae[^1].

Polymyxin B Sulfates

A cationic peptide antibiotic derived from Bacillus polymyxa, Polymyxin B targets Gram-negative bacteria by disrupting bacterial outer membranes. It is a cornerstone for multi-drug resistant infections, often administered intravenously or topically[^2].

Gramicidin

A mixture of linear polypeptides produced by Bacillus brevis, Gramicidin forms ion channels, disrupting cell membrane potential. It is mainly employed in topical formulations, especially in ophthalmic and dermatologic applications[^3].

Major Suppliers and Manufacturers

Global Market Overview

The global supply of Neomycin, Polymyxin B, and Gramicidin remains concentrated among a handful of specialized biotech and chemical manufacturers owing to their complex manufacturing processes, strict regulatory compliance, and the necessity for high purity standards.

Key Suppliers for Neomycin

Meiji Seika Pharma Co., Ltd. (Japan)
A leading producer, offering pharmaceutical-grade Neomycin sulfate widely used in both over-the-counter and prescription products. The company emphasizes high purity and compliance with pharmacopoeial standards[^4].
VWR International (USA)
Supplies research-grade Neomycin derivatives for laboratory applications, with some pharmaceutical-grade APIs available through distribution channels[^5].
Kowa Company, Ltd. (Japan)
Offers Neomycin sulfate for various clinical formulations with global distribution channels, emphasizing regulatory compliance.
Pharmaceutical Giants (India & China)
Several Indian companies such as Alkem Laboratories and Chinese manufacturers like Hisoar Pharmaceutical produce bulk Neomycin APIs conforming to international standards (e.g., USP, EP)[^6].

Key Suppliers for Polymyxin B Sulfate

Sequoia Pharmaceuticals, LLC (USA)
A notable supplier offering pharmaceutical-grade Polymyxin B sulfate, often used in multi-drug resistant infection treatment protocols.
Ch or International (India)
A significant regional producer, supplying bulk API to global markets with stringent quality control measures aligned with international pharmacopoeias[^7].
Bachem AG (Switzerland)
Provides research-grade Polymyxin B components suitable for formulation development.
Hetero Labs Ltd. (India)
Recognized for large-scale API manufacturing, including Polymyxin B, with export across multiple continents.

Key Suppliers for Gramicidin

Sigma-Aldrich (Merck Group) (Germany/USA)
Supplies research-grade Gramicidin, widely employed in laboratory and small-scale pharmaceutical research.
Cayman Chemical (USA)
Offers analytical grade Gramicidin suitable for pharmaceutical research and testing.
Synthelabo (France)
Historically engaged in the synthesis of peptide antibiotics, including bulk Gramicidin for specialized applications.
Indian & Chinese Specialty Manufacturers
Numerous regional producers supply Gramicidin APIs and formulations at various purity levels, often used in topical veterinary and human products[^8].

Market Dynamics and Supply Chain Factors

Manufacturing Complexities

Producing Neomycin, Polymyxin B, and Gramicidin involves complex fermentation processes, strict purification stages, and adherence to Good Manufacturing Practices (GMP). These complexities limit the number of capable producers and create supply concentration risks.

Regulatory Environment

Manufacturers operate under stringent regulatory frameworks (FDA, EMA, WHO), which enforce quality, purity, and stability standards. Regulatory approval processes can impact product availability and accelerate or delay market entry for new suppliers (e.g., WHO Prequalified APIs).

Global Supply Chain Challenges

Disruptions such as raw material shortages, geopolitical tensions, and the COVID-19 pandemic have intermittently constrained supplies, leading to market volatility and prompting procurement diversification efforts[^9].

Emerging Trends

Investment in biosynthetic and recombinant production methods could reduce reliance on fermentation and improve scalability.
Localized manufacturing is increasingly prioritized to mitigate geopolitical and logistical risks.

Regional and Emerging Suppliers

Emerging manufacturers in India, China, and Southeast Asia are expanding capacities, driven by increasing global demand and the trend of biosimilar and generic drug production. Many offer competitive pricing but must meet rigorous international standards.

Indian Industry

The Indian pharmaceutical sector is a dominant supplier of generic APIs, including Neomycin and Polymyxin B, with companies such as Hetero Labs, Vishwakarma Petrochemicals, and Aarti Industries expanding capacity and quality assurance standards.

Chinese Industry

Chinese firms like Hisoar Pharmaceutical and Shandong Weifang Pharmaceutical are gaining prominence through large-scale fermentation facilities, with some expanding into R&D for novel derivatives with enhanced efficacy or reduced toxicity.

Regulatory and Licensing Considerations

Supply reliability hinges on compliance with regulatory registrations, manufacturing authorizations, and export licenses. Suppliers often seek approvals from multiple agencies worldwide, which can prolong market entry and influence procurement strategies.

Furthermore, the increasing emphasis on quality certifications like ISO 9001 and cGMP standards remains crucial for market access, especially in stringent markets such as the US and EU.

Conclusion

The supply chain of Neomycin, Polymyxin B Sulfate, and Gramicidin is characterized by a limited global supplier base, primarily dominated by specialized bio-pharmaceutical manufacturers from Japan, India, and China. While established players maintain high-quality standards, emerging suppliers offer competitive pricing and capacity expansion. Ongoing regulatory scrutiny, manufacturing complexities, and geopolitical factors continue to shape the landscape, underscoring the importance of diversified sourcing strategies to secure uninterrupted supply.

Key Takeaways

Limited Global Suppliers: High manufacturing complexity ensures a concentrated supply chain, making reliability critical.
Regional Expansion: India and China are key growth regions, increasing their market share through capacity expansion and regulatory compliance.
Supply Chain Risks: Disruptions can lead to shortages; diversification and strategic inventory are essential for pharmaceutical companies.
Regulatory Compliance: High standards for APIs demand consistent GMP adherence, influencing supplier selection.
Innovation Trends: Biosynthetic and recombinant methods promise more scalable and reliable production in the future.

FAQs

Who are the primary global suppliers of Neomycin?
Leading suppliers include Meiji Seika Pharma (Japan), Indian firms like Alkem Laboratories, and Chinese manufacturers such as Hisoar Pharmaceutical, all adhering to high GMP standards[^4][^6].
Is Polymyxin B sulfate produced solely by Western companies?
No; major producers are based in India and China, such as Hetero Labs and Ch or International, providing bulk APIs for international markets[^7].
Can I source Gramicidin from regulatory-compliant suppliers easily?
Yes; research-grade Gramicidin is available from companies like Sigma-Aldrich and Cayman Chemical, although clinical-grade or pharmaceutical-grade sources are limited and often require special procurement channels[^8].
What factors affect the supply reliability of these antibiotics?
Production complexity, raw material availability, regulatory approvals, geopolitical issues, and global health crises like the pandemic all impact supply stability.
Are there emerging suppliers that could change the market dynamics?
Yes; Chinese and Indian manufacturers are expanding capacities and investing in new fermentation technologies, potentially increasing global supply and competitive pricing.

References

Katzung BG, Masters SB, Trevor AJ. Basic and Clinical Pharmacology. 14th ed. McGraw-Hill Education; 2021.
Kaye KS, et al. "Polymyxins for Multidrug-Resistant Gram-Negative Bacterial Infections." N Engl J Med. 2017;377(3):251-262.
Sinha P, et al. "Mechanisms of Action of Gramicidin A." Biochemistry. 2019;58(12):1609-1617.
Meiji Seika Pharma Co., Ltd. [Official website].
VWR International. Product catalogue.
Indian Pharmaceutical Directory 2022.
Hetero Labs Ltd. Annual Report 2022.
Sigma-Aldrich. Product details: Gramicidin.
UNCTAD. “Supply Chain Disruptions in Pharmaceuticals.” 2022.

Suppliers and packagers for NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN